Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2017
Accounting Basis: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional segments in biopharmaceuticals (haemophilia care, growth hormone therapy, and hormone replacement therapy). The company operates in more than 170 countries with approximately 42,100 employees. The 2017 Form 20-F incorporates by reference the company's statutory Annual Report 2017.
Key Financial Metrics (2017)
| Metric | 2017 (DKK Millions) | 2016 (DKK Millions) |
|---|---|---|
| Net Sales | 111,696 | 111,780 |
| Operating Profit | 48,967 | 48,432 |
| Net Profit | 38,130 | 37,925 |
| Earnings Per Share (Basic) | 15.42 | 14.99 |
| Free Cash Flow | 32,588 | 39,991 |
| Net Cash from Operating Activities | 41,168 | 48,314 |
| Total Assets | 102,355 | 97,539 |
| Net Assets (Equity) | 49,815 | 45,269 |
| Capital Expenditure (Net) | 8,700 | 7,100 |
| Dividend Per Share (Total) | 7.85 | 7.60 |
Debt and Liquidity: No long-term loans were outstanding as of December 31, 2017. Current debt was DKK 1,694 million. Financial resources (cash, cash equivalents, bonds, and undrawn credit facilities) totaled DKK 25,348 million. The company maintains a strong liquidity position with no material restrictions on fund transfers from subsidiaries.
Material Changes vs. Prior Period
- Revenue: Net sales remained relatively flat at DKK 111,696 million compared to DKK 111,780 million in 2016. This stability was driven by growth in the diabetes care segment, particularly the GLP-1 product Victoza (up 16% in DKK), offset by declines in other areas.
- Profitability: Operating profit increased slightly to DKK 48,967 million (up from DKK 48,432 million), and Net profit rose to DKK 38,130 million (up from DKK 37,925 million).
- Product Performance:
- Declines: Sales of Levemir (insulin) dropped significantly to DKK 14,118 million from DKK 17,083 million due to competition and patent expirations. Norditropin (growth hormone) sales fell to DKK 6,655 million from DKK 8,770 million, largely due to lower realized prices in the US. Vagifem sales declined sharply to DKK 1,108 million from DKK 2,995 million following the loss of exclusivity in the US in late 2016.
- Growth: Victoza sales reached DKK 23,173 million. New products like Tresiba, Ryzodeg, and Xultophy contributed to growth.
- Capital Allocation: The company completed a DKK 16 billion share repurchase program in January 2018 (initiated in Feb 2017) and announced a new DKK 14 billion program in February 2018. Capital expenditure increased to DKK 8.7 billion, focused on new production facilities in the US and Denmark.
Outlook, Risks, and Management Commentary
Outlook and Guidance:
- 2018 Expectations: Management expects average prices after rebates in the US to be lower in 2018 compared to 2017, predominantly driven by the basal insulin segment. Capital expenditure is expected to be around DKK 9.5 billion in 2018.
- Product Launches: Key launches expected in 2018 include Ozempic (once-weekly GLP-1) in the US, Fiasp (fast-acting insulin) in the US, and Tresiba in China.
- R&D: The company expects R&D spending to remain around 13% of sales. Significant projects include oral semaglutide and injectable semaglutide.
Risks and Contingencies:
- Patent Expirations: Key products face patent expirations. NovoLog/NovoRapid and NovoMix compound patents have expired in major markets. Levemir patents expire in 2019 in the US, Europe, and Japan. NovoSeven compound patents have expired, though formulation patents provide coverage until 2023/2024.
- Competition and Pricing: Intensified competition, particularly from biosimilars in the basal insulin segment (e.g., glargine biosimilar launched in Dec 2016), and pressure from US payers (PBMs) for higher rebates are driving down net prices.
- Regulatory and Legal: The company faces risks related to regulatory approvals, reimbursement policies, and potential product liability. The filing discloses ongoing business activities in Iran, including sales to government-controlled entities, though gross revenue from these transactions was under DKK 500 million in 2017.
Key Facts for Investor Verification
- Revenue Stability vs. Mix Shift: Verify the sustainability of flat top-line revenue given the significant decline in legacy products (Levemir, Norditropin, Vagifem) and the reliance on new product launches (Ozempic, Fiasp) to drive future growth.
- US Pricing Pressure: Assess the impact of declining net prices in the US market due to PBM rebates and biosimilar competition on future operating margins.
- Patent Cliff Exposure: Review the specific timeline for Levemir patent expirations (2019) and the company's strategy to mitigate sales erosion from biosimilars.
- Share Repurchase Program: Confirm the execution of the new DKK 14 billion share repurchase program announced in February 2018 and its impact on earnings per share.
- Iran Transactions: Note the disclosure of transactions with Iranian government-controlled entities and ensure compliance with relevant sanctions and regulatory requirements.